Shares of Aurobindo Pharma fell as much as 5 per cent to Rs 792 on Monday over concerns about inspection of the pharma company’s facilities by the US health regulator.
Aurobindo Pharma said the US Food and Drug Administrator (USFDA) did not issue Form 483 for the Unit III facility. “With regards to Unit VII, there were certain observations,” the Hyderabad-based company said.
It added: “The company is appropriately responding and this has no perceived impact on the operations and exports from the said facility.”
